Journal article
PET-detected pneumonitis following curative-intent chemoradiation in non-small cell lung cancer (NSCLC): recognizing patterns and assessing the impact on the predictive ability of FDG-PET/CT response assessment
A Iravani, GA Turgeon, T Akhurst, JW Callahan, M Bressel, SJ Everitt, S Siva, MS Hofman, RJ Hicks, DL Ball, MP Mac Manus
European Journal of Nuclear Medicine and Molecular Imaging | SPRINGER | Published : 2019
Abstract
Purpose: Inflammatory FDG uptake in the lung (PET-pneumonitis) following curative-intent radiotherapy (RT)/chemo-RT (CRT) in non-small cell lung cancer (NSCLC) can pose a challenge in FDG-PET/CT response assessment. The aim of this study is to describe different patterns of PET-pneumonitis to guide the interpretation of FDG-PET/CT and investigate its association with tumor response and overall survival (OS). Methods: Retrospective analysis was performed on 87 NSCLC patients in three prospective trials who were treated with radical RT (n = 7) or CRT (n = 80), with baseline and post-treatment FDG-PET/CT. Visual criteria were performed for post-treatment FDG-PET/CT response assessment. The grad..
View full abstractGrants
Awarded by Janssen Pharmaceuticals
Funding Acknowledgements
No funding was received for this study. However, the <SUP>18</SUP>F-FLT/18F-FDG study (Australian Clinical Trials Registry: ACTRN12611001283965) work was supported by the National Health and Medical Research Council (NHMRC) (grant number APP1003895) and the Victorian Cancer Agency. The <SUP>68</SUP>Ga-Ventilation/perfusion PET (Universal Trial Number: U1111-1138-4421) study was supported by funding from the NHMRC (grant number APP1038399) and from the Cancer Australia Priority-driven Collaborative Cancer Research Scheme (Project No. 1060919). Professor Hicks is supported by an NHMRC Practitioner Fellowship (APP1108050).